KNE Kane Biotech Inc

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the
development and commercialization of products that prevent and remove microbial
biofilms is pleased to announce it has received Notification Number "NN.TZMT"
from the Interim Notification Program for Low Risk Veterinary Health Products
(LRVHP) for a new StrixNB oral care product in Canada. With the issuance of this
notification number, the Company has cleared the final requirements for StrixNB
Oral Care Spray to enter the companion animal market in Canada. 


Health Canada in cooperation with the Canadian Animal Health Institute has
developed an interim notification program for low-risk veterinary health
products used in cats, dogs, and horses. The oral spray is the second product in
the Company's companion animal oral care portfolio and is complementary to
currently sold StrixNB Oral Care Water Additive. The new StrixNB application can
be sprayed directly on the teeth and tongue of the animal or can be applied to
treats and dental chews to assist in dental and oral hygiene. The Company has
also appointed a cGMP manufacturer for this new product. The pet oral care
market in the US is estimated at $450 million per year. 


In addition, over the summer the Company has developed a number of new products
with initial focus on the animal health sector. These products are progressing
through the development stages and include a StrixNB Oral Care Powder
application and two new topical dermatological formulations (under the brand
name DispersinB(R)). The new dermatological formulations developed include
antibiofilm-antimicrobial (non-antibiotic) otic drops for chronic ear infections
and an antibiofilm-antimicrobial (non-antibiotic) topical spray for atopic
dermatitis-associated infections. Regulatory packages for the above products
have been submitted to Health Canada's LRVHP program for review. 


"We are very pleased to obtain LRVHP clearance for our second StrixNB oral care
product as we continue to further develop an innovative portfolio of oral care
products for pet owners," stated Gord Froehlich, President and CEO of Kane
Biotech. "Effectiveness against biofilms continues to limit many oral and
topical dermatological products currently on the market presenting exciting
opportunities for our StrixNB & DispersinB portfolio of products."


About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development and
commercialization of products to prevent and remove biofilms. Biofilms are a
major cause of a number of serious medical problems including chronic infections
and medical device related infections. They develop on surfaces such as
catheters, prosthetic implants, teeth, lungs and the urogenital tract. Biofilms
are pervasive, costly to deal with and are involved in approximately 80% of all
human bacterial infections. The healing of chronic wounds alone costs the United
States health care system $20 Billion per year. 


Kane Biotech uses patent protected technologies based on molecular mechanisms of
biofilm formation/dispersal and methods for finding compounds that inhibit or
disrupt biofilms. The Company has evidence that these technologies have
potential to significantly improve the ability to prevent and/or destroy
biofilms in several medical and industrial applications. 


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release. 


Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, "forward-looking statements"). These forward-looking
statements relate to, among other things, our objectives, goals, targets,
strategies, intentions, plans, beliefs, estimates and outlook, including,
without limitation, our anticipated future operating results, and can, in some
cases, be identified by the use of words such as "believe", "anticipate",
"expect", "intend", "plan", "will", "may" and other similar expressions. In
addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking
statements.


These statements reflect management's current beliefs and are based on
information currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and actual results
may differ materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ materially from
these expectations include, among other things: Kane's early stage of
development, lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development, rapid
technological change, uncertainties related to forecasts, competition, potential
product liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters, management of
growth, partnerships for development and commercialization of technology,
effects of insurers' willingness to pay for products, system failures,
dependence on key personnel, foreign currency risk, risks related to regulatory
matters and risks related to intellectual property and other risks detailed from
time to time in Kane's filings with Canadian securities regulatory authorities,
as well as Kane's ability to anticipate and manage the risks associated with the
foregoing. Kane cautions that the foregoing list of important factors that may
affect future results is not exhaustive. When relying on Kane's forward-looking
statements to make decisions with respect to Kane, investors and others should
carefully consider the foregoing factors and other uncertainties and potential
events.


These risks and uncertainties should be considered carefully and prospective
investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this press release are
based upon what management believes to be reasonable assumptions, Kane cannot
provide assurance that actual results will be consistent with these
forward-looking statements. Kane undertakes no obligation to update or revise
any forward-looking statement. 


StrixNB(TM), DispersinB(R) and Aledex(R) are registered trademarks of Kane
Biotech Inc. All Rights Reserved 2013


FOR FURTHER INFORMATION PLEASE CONTACT: 
Pure Advertising and Marketing
Kam Thindal
President
604-566-9236 office or 604-488-9875 mobile
kam@puread.ca


Kane Biotech Inc.
Gord Froehlich
President & CEO
204-477-7592
204-474-7552 (FAX)
ir@kanebiotech.com
www.kanebiotech.com

Kane Biotech (TSXV:KNE)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Kane Biotech (TSXV:KNE)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024